References
- Sperling RA, Donohue MC, Raman R, et al. Trial of solanezumab in preclinical Alzheimer’s disease. N Eng J Med. 2023;389(12):1096–107. doi: 10.1056/NEJMoa2305032
- ClinicalTrials. Gov clinical trial of solanezumab for older individuals who may be at risk of memory loss (A4). [cited 2023 Nov 19]. Available from: https://clinicaltrials.gov/study/NCT02008357?term=SOLANEZUMAB&rank=6
- Mayo Clinic. Alzheimer’s disease. [cited 2023 Dec 19]. Available from: https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/symptoms-causes/syc-20350447
- Lu D, Dou F, Gao J. Development of amyloid beta-directed antibodies against Alzheimer’s disease: twists and turns. Drug Discov Ther. 2023;17:440–444. doi: 10.5582/ddt.2023.01215
- U.S. Food & Drug Administration. FDA grants accelerated approval for Alzheimer’s drug. [cited 2023 Dec 19]. Available from: https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-alzheimers-drug
- U.S. Food & Drug Administration. FDA converts novel Alzheimer’s disease treatment to traditional approval. [cited 2023 Dec 19]. Available from: https://www.Fda.gov/news-events/press-announcements/fda-converts-novel-alzheimers-disease-treatment-traditional-approval
- Van Dyck CH, Swanson CJ, Aisent P, et al. Lecanemab in early Alzheimer’s disease. N Engl J Med. 2023;388(1):9–21. doi: 10.1056/NEJMoa2212948
- Solopova E, Romero-Fernandez W, Harmsen H, et al. Fatal iatrogenic cerebral β-amyloid-related arteritis in a woman treated with lecanemab for Alzheimer’s disease. Nat Commun. 2023;14(1):8220. doi: 10.1038/s41467-023-43933-5
- Farlow M, Arnold SE, van Dyck CH, et al. Safety and biomarker effects of solanezumab in patients with Alzheimer’s disease. Alzheimers Dement. 2012;8(4):261–271. doi: 10.1016/j.jalz.2011.09.224
- Siemers E, Friedrich S, Dean R, et al. Safety and changes in plasma and cerebrospinal fluid amyloid β after a single administration of an amyloid β monoclonal antibody in subjects with alzheimer disease. Clin Neuropharmacol. 2010;33(2):67–73. doi: 10.1097/WNF.0b013e3181cb577a
- Doody RS, Thomas RG, Farlow M, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer’s disease. N Engl J Med. 2014;370(4):311–321. doi: 10.1056/NEJMoa1312889
- Siemers ER, Sundell KL, Carlson C, et al. Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer’s disease patients. Alzheimers Dement. 2016;12(2):110–120. doi: 10.1016/j.jalz.2015.06.1893
- Honig LS, Vellas B, Woodward M, et al. Trial of solanezumab for mild dementia due to Alzheimer’s disease. N Eng J Med. 2018;378(4):321–30. doi: 10.1056/NEJMoa1705971
- Doggrell SA. Grasping at straws: the failure of solanezumab to modify mild Alzheimer’s disease. Expert Opin Biol Ther. 2018;18(12):1189–92. doi: 10.1080/14712598.2018.1543397
- Holdridge KC, Yaari R, Hoban DB, et al. Targeting amyloid β in Alzheimer’s disease: meta-analysis of low-dose solanezumab in Alzheimer’s disease with mild dementia studies. Alzheimer’s & Dementia. 2023;19(10):4619–4628.
- ClinicalTrials.gov A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer’s Disease (ExpeditionPRO). [cited 2023 Dec 19]. Available from: https://clinicaltrials.gov/study/NCT02760602?intr=Solanezumab&rank=2
- Kepp KR, Robakis NK, Høilund-Carlsen P, et al. The amyloid cascade hypothesis: an updated critical review. Brain. 2023;146(10):3969–3990. doi: 10.1093/brain/awad159
- Vaz M, Silva V, Monterio S, et al. Role of aducanumab in the treatment of Alzheimer’s disease: challenges and opportunities. Clin Interv Aging. 2022;17:797–810.
- ClinicalTrials. Gov a study to evaluate safety and tolerability of aducanumab in participants with Alzheimer’s disease who had Previously participated in the aducanumab studies 221AD103, 221AD301, 221AD302 and 221AD205. [cited 2023 Dec26]. Available from: https://clinicaltrials.gov/study/NCT04241068?term=aducanumab&rank=4#more-information
- Kurkinen M. Lecanemab (Leqembi) is not the right drug for patients with Alzheimer’s disease. Adv Clin Exp Med. 2023;32(9):943–947.
- Wu W, Ji Y, Wang Z, et al. The FDA-approved anti-amyloid-β monoclonal antibodies for the treatment of Alzheimer’s disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Med Res. 2023;28(1):544. doi: 10.1186/s40001-023-01512-w